medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2006, Number 4

<< Back Next >>

Arch Neurocien 2006; 11 (4)

Switching from haloperidol to olanzapine in a sample of peruvian patients with schizophrenia and extrapyramidal symptoms

Tamayo J, Femández A, Holguín J, Adrianzén C, Vílchez L, Ruiz E, Saavedra B

Language: Spanish
References: 55
Page: 232-240
PDF size: 247.84 Kb.


ABSTRACT

Objective: efficacy and safety of change from haloperidol to olanzapine was evaluated in a sample of homogeneous population of Peruvian schizophrenic patients with extrapyramidal symptoms. Methods: thirty Peruvian patients with schizophrenia (DSM-IV criteria) were changed from haloperidol ≤20 mg/d to olanzapine 10 to 20 mg/d for eight weeks. Potential changes in the extrapyramidal symptoms observed in all the patients at study baseline were evaluated using Simpson Angus Scale (SAS) and Barnes Akathisia Scale (BAS). Brief Psychiatric Rating Scale (BPRS), positive and negative Syndrome Scale (PANSS) and Clinical Global Impression Severity (CGI-S) were also administered to evaluate changes in efficacy. Additionally, Quality of Life Scale (QLS) was used and adverse events were registered. Results: multivariate analysis found astatistical decrease in SAS, BPRS, PANSS and QLS (p‹0.001) and BAS (p‹ 0.006) change was registered from the first week of olanzapine administration in all scales. Forty percent of patients experienced some type of adverse events during the trial, with constipation and weight gain being reported most frequently. Conclusions: switching from haloperidol to olanzapine could offer not only a reduction in extrapyramidal symptoms, but also an improvement in efficacy measures and quality of life in the treatment of this sample of Peruvians patients with schizophrenia.


REFERENCES

  1. 1.Schultz SC, McGorry P. Traditional antipsychotic medica-tionscontemporary clinical use. Schizophrenia and mood disordersthe new drug therapies in clinical practice. Oxford (UK): Butterworth Heinemann; 2000.

  2. 2.Kampman O, Lehtinen K. Compliance in psychoses. ActaPsychiatr Scand 1999;100:167-75.

  3. Leucht S, Barnes TR, Kissling W, Engel RR Correll C, Kane JM.Relapse prevention in schizophrenia with new-generationantipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry2003;160:1209-22.

  4. 4.Kane JM. Tardive dyskinesia: epidemiological and clinicalpresentation. In: Blomm FE, Kupfer, DJ eds. Psychophar-macology the fourth generation of progress. New York: RavenPress; 1995.

  5. 5.Schultz SE. Schizophrenia: somatic treatment. In: Sadock BJ,Sadock VA, eds. Kaplan & Sadock’s. Comprehensive textbookof psychiatry. 7ht ed. Baltimore: Williams & Wilkins; 1995.

  6. 6.Leucht S, Wahlbeck K, Hamann J, Kissling W. New generationantipsychotics versus low-potency conventional antipsychotics:a systematic review and meta-analysis. Lancet 2003;361:1581-9.

  7. 7.Costa e Silva J, Alvarez N, Mazzotti G, Gattaz WF, Ospina J,Larach V, et al. Olanzapine as alternative Therapy for PatientsWith Haloperidol-Induced Extra pyramidal Symptoms: Resultsof a Multicenter Collaborative Trial in Latin America. J ClinPsychophamlacology 2001; 21:375-81.

  8. 8.Rovner J, Battaglia H, Carrera J, Corrales A, Guerstein S, Liottaet al. Grupo Argentino de Investigación en Neurociencias. Pa-saje de pacientes psicóticos de haloperidol a olanzapina. Unestudio multicéntrico abierto de seguridad y eficacia. Acta Psi-quiátrica y Psicológica de América Latina 2001;47:131-8.

  9. Simpson GM, Angus JWS. A rating scale for extra pyramidalside effects. Acta Psychiatr Scand 1970;212:511-9.

  10. 10.Barnes TRE. A rating scale for drug-induced akathisia. Br JPsychiatry 1989;154:672-6.

  11. 11.Kay SR, Opler LA, Fiszbein A. eds. Positive and negativesyndrome scale (PANSS) Manual. North Tonawanda (NY):Multi Health Systems; 1986.

  12. Overall JE, Gorham DR. The brief psychiatric rating scale.Psychol Rep 1962;10:799-812.

  13. 13.Guy W ed. ECDEU Assessment manual for psychophar-macology. Washington DC: US Department of Health,Education and Welfare Publications; 1976.

  14. Heinrichs DW, Hanlon TE, Carpenter WT Ir. The Quality of LifeScale: an instrument for rating the schizophrenic deficitsyndrome. Schizophr Bull 1984;10:388-98.

  15. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM,Kane JM. An integrated analysis of acute treatment-emergentextrapyramidal syndrome in patients with schizophrenia duringolanzapine clinical trials: comparisons with placebo, haloperidol,risperidone, or clozapine. J Clin Psychiatry 2003;64:898-906.

  16. Seeman P, Tallerico T. Antipsychotic drugs which elicit little orno parkinsonism bind more loosely than dopamine to brain D2receptors, yet occupy high levels of these receptors. MolPsychiatry 1998;3:123-34.

  17. 17.Moore NA, Tye NC, Axton MS, Risius Fe. The behavioralpharmacology of olanzapine a novel “atypical” antipsychoticagent. J Pharrnacol Exp Ther 1992;262:545-51.

  18. Moore NA, Calligaro DO. The pharmacology of olanzapineand other new antipsychotic agents. Curr Opin Invest Drugs1993;2:281-93.

  19. Nyberg S, Nakashima Y, Nordstrom AL, Halldin C, Farde L.Positron emission tomography of in-vivo binding characteristicsof atypical antipsychotic drugs. Review of D2 and 5-HT2 recep-tor occupancy studies and clinical response. Br J Psychiatry1996; 29(Suppl):40-44.

  20. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA,Tye NC, et al. Radio receptor binding profile of the atypicalantipsychotic olanzapine. Neuropsychophamacology 1996;14:87-96.

  21. Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapineincreases in vivo dopamine and norepinephrine release in ratprefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 1998;136:153-61.

  22. 22.Stockton ME, Rasmussen K. Olanzapine, a novel atypicalantipsychotic, reverses d-amphetamine-induced inhibition ofmidbrain dopamine cells. Psychopharmacology (Berl) 1996;124:50-6.

  23. Beasley CM Jr, Tollefson GD, Tran P, Satter Lee W, Sanger T,Hamilton S. Olanzapine versus placebo and haloperidol: acutephase results of the North American double-blind olanzapinetrial. Neuropsychopharmacology 1996; 14: 111-23.

  24. Tollefson GD, Beasley CM Ir, Tran PV, Street JS, Krueger JA,Tamura RN. Olanzapine versus haloperidol in the treatment ofschizophrenia and schizo-affective and schizophreniformdisorders: results of an international collaborative trial. Am JPsychiatry 1997;154:457-65.

  25. Remington G. Understanding antipsyehotic “atypicality”: aclinical and pharmacological moving target. J PsychiatryNeurosci 2003;28:275-84.

  26. Purdon SE, Jones BD, Stip E, Labelle A, Addington D.Neuropsychological change in early phase schizophrcniaduring 12 months of treatment with olanzapine, risperidone, orhaloperidol. The Canadian Collaborative Group for research inschizophrenia. Arch Gen Psychiatry 2000;57:249-58.

  27. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychoticolanzapine versus haloperidol or placebo on anxious anddepressive symptoms accompanying schizophrenia. BiolPsychiatry 1998;43:803-10.

  28. Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, Beasley CMJr. Olanzapine versus haloperidol in the treatment ofschizoaffective disorder. Acute and long-term therapy. Br JPsychiatry 1999;174:15-22.

  29. Lieberman J, Tollefson GD, Charles C, Zipursky R, Sharma T,Kahn RS, et al. Tohen M for the HGDH Study Group.Antipsychotie drug effects on brain morphology in first-episode psyehosis. Arch Gen Psychiatry 2001; 62: 361-70.

  30. Konradi C, Heckers S. Molecular aspects of glutamatedysregulation: implications for schizophrenia and its treatment.Pharmacol ther 2003;97:153-79.

  31. 31.Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA.Effects of ketamine and N-methyl-D-aspartate on glutamateand dopamine release in the rat prefrontal cortex: modulationby a group II selective metabotropic glutamate receptoragonist LY379268. Neuroscience 2003;117:697-706.

  32. 32.Maragakis NJ, Rothstein JD. Glutamate transporters inneurologic disease. Arch Neurol 2001;58:365-70.

  33. 33.Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypicalantipsychotic dmgs vs haloperidol to protect PC12 cellsagainst MPP+-induced apoptosis. Eur J Neurosci 2003;17:1563-70.

  34. 34.Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine andolanzapine upregulate bcl-2 mRNA and protein in rat frontalcortex and hippocampus. Brain Res 2004;1010:81-6.

  35. Bai O, Chan-Fourney J, Bowen R, Keegan D, Li XM.Expression of brain-derived neurotrophic factor mRNA in rathippocampus after treatment with antipsychotic drugs. JNeurosci Res 2003;71:127-31.

  36. Wang HD, Dunnavant FD, Jarman T, Deutch AY. Effects ofantipsychotic drugs on neurogenesis in the forebrain of theadult rat. Neuropsychopharmacology 2004;29: 1230-8.

  37. Kodama M, Fujioka T, Duman RS. Chronic olanzapine orfluoxetine administration increases cell proliferation inhippocampus and prefrontal cortex of adult rat. Biol Psychiatry2004;56:570-80. Erratum in: Biol Psychiatry 2005;57:199.

  38. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC.Antipsychotic-induced weight gain: a comprehensive researchsynthesis. Am J Psychiatry 1999; 156: 1686-96.

  39. Beasley CM Jr, Grundy S, Gannon KS, Berg PH. Overview ofthe safety of Olanzapine. In: Tran P, Bymaster FP, Tye NC,Herrera JM, Breier A, Tollefson GD, editors. Olanzapine(Zyprexa@): a novel antipsychotic. Philadelphia: LippincottWilliams & Wilkins; 2000.

  40. Kinon BJ, Basson BR Gilmore JA, Tollefson GD. Long-termolanzapine treatment: weight change and weight-related healthfactors in schizophrenia. J Clin Psychiatry 2001;62:92-100.

  41. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, SteinbergS, Ernsberger P, et al. H1-histamine receptor affinity predictsshort-term weight gain for typical and atypical antipsychoticdrugs. Neuropsychopharmacology 2003;28:519-26.

  42. Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H,Kangawa K, et al. Olanzapine increases plasma ghrelin levelin patients with schizophrenia. Psychoneuroendocrinology2001;30: 106-10.

  43. Dumortier G, Cabaret W, Stamatiadis L, Saba G, BenadhiraR, Rocamora JF. Hepatic tolerance of atypical antipsy-choticdrugs. Encephale 2002;28:542-51.

  44. Koller EA, Schneider B, Bernett K. Clozapine-AssociatedDiabetes mellitus. J Med 2001;111:716-23.

  45. Koller EA, Doraiswamy PM. Quetiapine-Associated Diabetes.Poster Presented at the American Psychiatric Association Mee-ting May, 2003 San Francisco.

  46. Koller EA, Doraiswamy PM. Olanzapine-Associated Diabetesmellitus. Pharmacotherapy 2002;22:841-52.

  47. Koller EA, Doraiswamy PM, Cross JT. Risperidone-AssociatedDiabetes. Pharmacotherapy 2003;23:735-44.

  48. Lorenz WF. Sugar tolerance in dementia praecox and othermental disorders. Arch Neurol Psychiatry 1922;8:184-96.

  49. 49.Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action ofinsulin in schizophrenia. Am J Psychiatry 1945;102:108-10.

  50. Langfeldt G. The insulin tolerance test in mental disorders. ActaPsychiatr Scand 1952;80(suppl.):189-200.

  51. Keskiner A, Toumi AE, Bousquet T. Psychotropic drugs, dia-betes, and chronic mental patients. Psychosomatics 1973; 16:176-81.

  52. McKee HA, D’ Arcy PF, Wilson PJK. Diabetes in schizophrenia:a preliminary study. J Clín Hosp Pharmacy 1986;11:297-9.

  53. Mukherjee S, Sclmur DB, Reddy R. Family history of type 2diabetes in schizophrenic patients. Lancet 1989; 1:495.54. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL.Diabetes mellitus in schizophrenic patients. Compr Psyduatry1996;37:68-97.

  54. Ryan MC, Collins P, Thakore JH. lmpaired fasting glucosetolerance in first-episode, drug-naive patients with schizo-phrenia. Am J Psychíatry 2003;160:284-9.

  55. Thakore JH, Mann JN, Vlahos l, Martin A, Reznek R. Increasedvisceral fat distribution in drug-naive and drug-free patientswith schizophrenia. lnt J Obes Relat Metab Disord 2002;26:137-41.




2020     |     www.medigraphic.com